These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 2041455)
21. Purification and characterization of a bovine cerebral cortex cell surface sialoglycopeptide that inhibits cell proliferation and metabolism. Sharifi BG; Johnson TC; Khurana VK; Bascom CC; Fleenor TJ; Chou HH J Neurochem; 1986 Feb; 46(2):461-9. PubMed ID: 2416876 [TBL] [Abstract][Full Text] [Related]
22. Effects of genistein on the growth and cell cycle progression of normal human lymphocytes and human leukemic MOLT-4 and HL-60 cells. Traganos F; Ardelt B; Halko N; Bruno S; Darzynkiewicz Z Cancer Res; 1992 Nov; 52(22):6200-8. PubMed ID: 1330289 [TBL] [Abstract][Full Text] [Related]
23. Role of calcium in growth inhibition induced by a novel cell surface sialoglycopeptide. Betz NA; Westhoff BA; Johnson TC J Cell Physiol; 1995 Jul; 164(1):35-46. PubMed ID: 7790395 [TBL] [Abstract][Full Text] [Related]
24. Cell cycle and transcriptional control of human myeloid leukemic cells by transforming growth factor beta. Hu X; Zuckerman KS Leuk Lymphoma; 2000 Jul; 38(3-4):235-46. PubMed ID: 10830731 [TBL] [Abstract][Full Text] [Related]
25. CeReS-18, a novel cell surface sialoglycopeptide, induces cell cycle arrest and apoptosis in a calcium-sensitive manner. Betz NA; Fattaey HK; Westhoff BA; Paulsen AQ; Johnson TC Breast Cancer Res Treat; 1997 Jan; 42(2):137-48. PubMed ID: 9138603 [TBL] [Abstract][Full Text] [Related]
26. Inhibition of epidermal growth factor-stimulated DNA synthesis by a bovine sialoglycopeptide inhibitor occurs at an intracellular level. Bascom CC; Sharifi BG; Johnson TC J Cell Biochem; 1987 Aug; 34(4):283-91. PubMed ID: 3497936 [TBL] [Abstract][Full Text] [Related]
27. Cell surface interaction is sufficient for the biological activity of a bovine sialoglycopeptide inhibitor. Sharifi BG; Bascom CC; Johnson TC Biochem Biophys Res Commun; 1986 Feb; 134(3):1350-7. PubMed ID: 3947369 [TBL] [Abstract][Full Text] [Related]
28. A fraction isolated from Ehrlich ascites carcinoma as an antitumor and differentiating agent against human leukemic cell ML-2. Sur P; Nandi N; Ghosh P; Ghosh NC Neoplasma; 2000; 47(2):114-7. PubMed ID: 10985477 [TBL] [Abstract][Full Text] [Related]
29. Suppression of leukemic growth by HFDI and LAI-615. Wu KF; Song YH; Li HZ; Rao Q; Zhu YM Ann N Y Acad Sci; 1991; 628():153-5. PubMed ID: 2069295 [No Abstract] [Full Text] [Related]
30. Inhibition of cyclin D-cdk activity in cell cycle arrest of Swiss 3T3 cells by CeReS-18, a novel cell regulatory sialoglycopeptide. Zhao K; Fattaey HK; Quinton TM; Johnson TC Exp Cell Res; 1998 Oct; 244(1):295-301. PubMed ID: 9770372 [TBL] [Abstract][Full Text] [Related]
31. Effects of sodium stibogluconate on differentiation and proliferation of human myeloid leukemia cell lines in vitro. Pathak MK; Hu X; Yi T Leukemia; 2002 Nov; 16(11):2285-91. PubMed ID: 12399974 [TBL] [Abstract][Full Text] [Related]
32. Identification of a cell surface component of Swiss 3T3 cells associated with an inhibition of cell division. Lakshmanarao SS; Toole-Simms WE; Fattaey HK; Leach RJ; Johnson TC Exp Cell Res; 1991 Aug; 195(2):412-5. PubMed ID: 2070822 [TBL] [Abstract][Full Text] [Related]
33. Carnosic acid inhibits proliferation and augments differentiation of human leukemic cells induced by 1,25-dihydroxyvitamin D3 and retinoic acid. Steiner M; Priel I; Giat J; Levy J; Sharoni Y; Danilenko M Nutr Cancer; 2001; 41(1-2):135-44. PubMed ID: 12094616 [TBL] [Abstract][Full Text] [Related]
34. Induction of differentiation and arrest of proliferation of mouse myeloid leukemia M1 cells. Hayashi M; Okabe-Kado J; Hozumi M Exp Cell Res; 1982 Jun; 139(2):422-7. PubMed ID: 6953014 [No Abstract] [Full Text] [Related]
35. The role of calcium in differentiation of leukemic cell lines. Rephaeli A; Aviram A; Rabizadeh E; Englender T; Shaklai M Cancer Biochem Biophys; 1990 Apr; 11(2):119-25. PubMed ID: 2383856 [TBL] [Abstract][Full Text] [Related]
36. Characterization of sublines of HL-60 human leukemia cells resistant to induction of differentiation by butyric acid. Fischkoff SA; Hoessly MC; Rossi RM Leukemia; 1990 Apr; 4(4):302-6. PubMed ID: 2164121 [TBL] [Abstract][Full Text] [Related]
37. Receptor occupancy by a bovine sialoglycopeptide inhibitor correlates with inhibition of protein synthesis. Bascom CC; Sharifi BG; Johnson TC J Cell Physiol; 1986 Aug; 128(2):202-8. PubMed ID: 3733887 [TBL] [Abstract][Full Text] [Related]
38. Cell cycle control by p53 in normal (3T3) and chemically transformed (Meth A) mouse cells. I. Regulation of p53 expression. Steinmeyer K; Maacke H; Deppert W Oncogene; 1990 Nov; 5(11):1691-9. PubMed ID: 2267135 [TBL] [Abstract][Full Text] [Related]
39. Cell agglutination by a novel cell surface sialoglycopeptide inhibitor and the relationship between its protease and biological activities. Sobieski RJ; Johnson TC; Sharifi BG; Bascom CC Life Sci; 1986 May; 38(20):1883-8. PubMed ID: 3517541 [TBL] [Abstract][Full Text] [Related]
40. STAT3 activation is a critical step in gp130-mediated terminal differentiation and growth arrest of a myeloid cell line. Minami M; Inoue M; Wei S; Takeda K; Matsumoto M; Kishimoto T; Akira S Proc Natl Acad Sci U S A; 1996 Apr; 93(9):3963-6. PubMed ID: 8632998 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]